I-Mab - ADR Peer Comparison
$3.98
$0.02
(0.51%)
As on 31-Dec-2025 09:30EDT
Market cap
$534 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.8
Div. Yield
0 %
Edit
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
534 | 15,933 | 13,215 | 11,972 | 10,883 |
Revenue ($ Mln) |
-- | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
-24.54 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
-- | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
-10.74 | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
-- | -- | 271.67 | -- | -- |
Price-To-Book |
1.76 | 123.68 | 18.72 | 1.79 | 130.86 |
Income Statement ($ Mln)
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 221.90 | 675.04 | 4,439.00 | 385.69 |
|
Cost of Revenue
|
0.00 | 3.88 | 10.88 | 2,530.00 | 33.30 |
|
Gross Profit
|
-- | 218.02 | 664.16 | 1,909.00 | 352.39 |
|
Operating Expenses
|
33.47 | 811.00 | 527.21 | 1,658.00 | 632.95 |
|
Operating Profit (EBIT)
|
-33.47 | -592.97 | 136.95 | 251.00 | -280.56 |
|
Other Income
|
0.00 | -- | -- | -- | -- |
|
Profit before Tax
|
-26.33 | -542.19 | 161.49 | 488.00 | -287.13 |
|
Provision for Tax
|
0.00 | 1.15 | 20.28 | 150.00 | 0.09 |
|
Profit after Tax (Net Income)
|
-24.54 | -535.76 | 139.73 | 338.00 | -287.22 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
0.00 | -- | -- | -- | -- |
Liabilities ($ Mln)
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
258.92 | -1,467.90 | 679.59 | 6,096.00 | 57.02 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
2.40 | 2,222.55 | 20.19 | 5,203.00 | 281.38 |
|
Current Liabilities
|
16.09 | 154.40 | 140.77 | 1,315.00 | 230.10 |
|
Total Liabilities
|
212.68 | 919.34 | 840.55 | 12,614.00 | 568.50 |
Assets ($ Mln)
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
44.64 | 198.65 | 368.95 | 9,399.00 | 83.43 |
|
Current Assets
|
232.78 | 720.69 | 471.60 | 3,215.00 | 485.06 |
|
Total Assets
|
212.68 | 919.34 | 840.55 | 12,614.00 | 568.50 |
|
Total Debt*
|
0.00 | 1,730.58 | 6.94 | 4,321.00 | 192.96 |
|
Net Current Assets
|
216.68 | 566.29 | 330.83 | 1,900.00 | 254.96 |
Cashflow ($ Mln)
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-52.67 | -520.73 | 198.07 | 541.00 | -128.41 |
|
Cash Flow from Investing Activities
|
-136.02 | 60.78 | -177.60 | 1,158.00 | -0.27 |
|
Cash from Financing Activities
|
-0.34 | 748.46 | -28.35 | -1,492.00 | 57.84 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-15.78 | -165.29 | 23.42 | 3.02 | -91.57 |
|
ROE (%)
|
-10.74 | 37.97 | 23.56 | 5.49 | -231.63 |
|
ROA (%)
|
-9.12 | -73.11 | 19.11 | 2.51 | -49.66 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -241.44 | 20.70 | 7.61 | -74.47 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-1.00 | 22.85 | 0.40 | 0.00 | 0.43 |
|
EBIT Growth (%)
|
93.05 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
40.80 | 16.70 | 31.65 | 127.46 | -20.05 |
|
EPS Growth (%)
|
-310.25 | 0.23 | 0.23 | 1.27 | -0.17 |
|
Book Value Growth (%)
|
-63.48 | -- | -- | -- | -- |
Valuation Ratios
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.98 | -9.70 | 42.72 | 17.71 | -14.30 |
|
Price / Book Value
|
0.79 | -3.54 | 8.78 | 0.98 | 72.04 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.03 | -14.30 | 34.35 | 6.61 | -14.62 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -1.18 | 0.01 | 0.71 | 3.38 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.00 | 0.01 | 0.06 |
|
Current Ratio
|
14.47 | 4.67 | 3.35 | 2.44 | 2.11 |
|
Quick Ratio
|
14.47 | 4.67 | 3.26 | 1.25 | 2.04 |
|
Interest Coverage
|
-- | -4.46 | -- | 2.44 | -42.71 |
Operating Efficiency Ratios
| I-Mab - ADR | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 2.13 | 8.60 | 19.96 | 36.82 |
|
Asset Turnover
|
0.00 | 0.30 | 0.92 | 0.33 | 0.67 |
|
Receivable days
|
-- | 5.33 | 31.08 | 78.00 | 112.13 |
|
Inventory Days
|
-- | 784.23 | 338.03 | 238.86 | 169.27 |
|
Payable days
|
-- | 954.71 | 549.99 | 40.86 | 617.89 |
|
Cash Conversion Cycle
|
-- | -165.15 | -180.88 | 276.00 | -336.48 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
